{
  "schema_version": "1.0",
  "type": "article",
  "title": "諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品",
  "url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.md",
  "lang": "zh-Hant",
  "date": "2026-07-15",
  "publish_at": "2026-07-15T08:00:00+08:00",
  "updated_at": "2026-07-15",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "商業分析系列",
    "Treg",
    "免疫耐受",
    "細胞療法",
    "自體免疫",
    "移植",
    "CMC",
    "台寶生醫",
    "臨床開發",
    "生技投資"
  ],
  "summary": "諾貝爾獎照亮 Treg 科學，但產業價值要看免疫耐受能否被做成可放行、可追蹤、可定價、可複製的產品，而不是急著追逐未經核實的第一款獲批敘事。",
  "key_points": [],
  "facts": [],
  "sections": [
    "01｜諾貝爾獎照亮的，是免疫系統的煞車",
    "02｜Treg 為什麼難做：一顆分子解不了，一套秩序工程才解得動",
    "03｜全球賽道正在分成三條路",
    "04｜台灣怎麼看：台寶先放進觀察座標",
    "05｜風險：第一個獲批藥不能靠二手敘事",
    "結語｜Treg 的下一關，是把免疫學做成可控產品",
    "參考資料",
    "免責聲明"
  ],
  "references": [
    {
      "title": "[NobelPrize.org",
      "source": "The Nobel Prize in Physiology or Medicine 2025]",
      "date": "",
      "url": "https://www.nobelprize.org/prizes/medicine/2025/summary/"
    },
    {
      "title": "[Nektar Therapeutics",
      "source": "Our Pipeline]",
      "date": "",
      "url": "https://www.nektar.com/our-pipeline/"
    },
    {
      "title": "[Sonoma Biotherapeutics",
      "source": "Pipeline]",
      "date": "",
      "url": "https://sonomabio.com/platform-pipeline/pipeline/"
    },
    {
      "title": "[Quell Therapeutics",
      "source": "Pipeline]",
      "date": "",
      "url": "https://www.quell-tx.com/our-science/pipeline/"
    },
    {
      "title": "[Quell Therapeutics",
      "source": "Technology Platform]",
      "date": "",
      "url": "https://www.quell-tx.com/our-science/technology-platform/"
    },
    {
      "title": "[台寶生醫",
      "source": "TRK-001 取得衛福部原則同意執行第二期腎臟移植排斥預防臨床試驗]",
      "date": "",
      "url": "https://twbio-thera.com/tw/news/1/16"
    }
  ],
  "images": [
    {
      "alt": "Treg 科學從免疫耐受概念走向可製造、可追蹤與可交付的細胞產品",
      "url": "https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-01.webp"
    },
    {
      "alt": "調節性 T 細胞像免疫系統的煞車，在必要時抑制過度反應並維持周邊免疫耐受",
      "url": "https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-02.webp"
    },
    {
      "alt": "Treg 產品化可分為體內誘導或擴增、體外細胞療法與工程化 Treg 三條路徑",
      "url": "https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-03.webp"
    },
    {
      "alt": "台寶 TRK-001 自體 Treg 從採血、體外擴增、腎移植後回輸到第二期試驗的產品化路徑",
      "url": "https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-04.webp"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-07-15）。諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品。https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {
    "en": "2026-07-15-treg-immune-tolerance-productization-en.html"
  }
}